C
39.94
0.01 (0.03%)
| Penutupan Terdahulu | 39.93 |
| Buka | 39.93 |
| Jumlah Dagangan | 472,737 |
| Purata Dagangan (3B) | 412,321 |
| Modal Pasaran | 1,165,795,072 |
| Harga / Jualan (P/S) | 3.36 |
| Harga / Buku (P/B) | 2.46 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Keuntungan | -1.46% |
| Margin Operasi (TTM) | -31.74% |
| EPS Cair (TTM) | -0.190 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.87% |
| Nisbah Semasa (MRQ) | 9.37 |
| Aliran Tunai Operasi (OCF TTM) | 65.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 44.64 M |
| Pulangan Atas Aset (ROA TTM) | -1.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -1.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Castle Biosciences, Inc. | Menurun | Menaik |
AISkor Stockmoo
-0.7
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.70 |
|
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.98% |
| % Dimiliki oleh Institusi | 93.02% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 52.00 (Lake Street, 30.20%) | Beli |
| Median | 50.00 (25.19%) | |
| Rendah | 41.00 (Baird, 2.65%) | Beli |
| Purata | 48.00 (20.18%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 38.87 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 26 Jan 2026 | 47.00 (17.68%) | Beli | 43.04 |
| 05 Jan 2026 | 43.00 (7.66%) | Beli | 39.00 | |
| Lake Street | 12 Jan 2026 | 52.00 (30.20%) | Beli | 39.66 |
| Canaccord Genuity | 22 Dec 2025 | 50.00 (25.19%) | Beli | 41.39 |
| BTIG | 12 Dec 2025 | 50.00 (25.19%) | Beli | 38.63 |
| 05 Nov 2025 | 38.00 (-4.86%) | Beli | 33.57 | |
| Baird | 04 Nov 2025 | 41.00 (2.65%) | Beli | 31.63 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MAETZOLD DEREK J | - | 40.86 | -4,017 | -164,135 |
| Jumlah Keseluruhan Kuantiti Bersih | -4,017 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -164,135 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 40.86 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pegawai | 20 Jan 2026 | Jual automatik (-) | 4,017 | 40.86 | 164,135 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |